Case study.

Abstract

Publication Data featured in Molecular Cancer Therapeutics, Brack et al. 2014. Fynomer C12 Epitope Covagen developed COVA208, a bispecific FynomAb which targets two epitopes on HER2. This included a novel moiety, Fynomer C12, which was combined with a region of pertuzumab to create a bispecific that demonstrated superior activity to trastuzumab and pertuzumab in tumor models. Covagen required detailed epitope information for the novel moiety (Fynomer C12). This allowed them to better understand the molecule’s mechanism-of-action and to demonstrate its novelty.